A magnetic resonance and ultrasound-based method for assessing the efficacy of neoadjuvant therapy for soft tissue sarcomas

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500105933

Enrollment

Unknown

Registered

2025-07-15

Start date

2025-07-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

soft tissue sarcomas

Interventions

Trial group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with clear pathologic findings and a definitive diagnosis of soft tissue sarcoma. 2. Patients requiring neoadjuvant therapy. 3. Patients with well-established imaging data.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete medical information. 2. Patients with contraindications to ultrasound contrast agents (unstable angina, allergies). 3. Patients undergoing invasive procedures at other hospital. 4. Patients with poor basal status and EOCG score =1. 5. Patients who are unable to cooperate with MRI or ultrasound.

Design outcomes

Primary

Measure	Time frame
Pathologic tumor necrosis rate;Vascularization index Pre-chemo, During chemo, Pre-surgery;Tumor stiffness;Microvessel density, diameter, spacing, complexity, tortuosity, flow velocity, blood volume, Perfusion index;Tumor volume;Time to peakPeak intensityWash-in slopeTime to 50% washout;	—

Secondary

Measure	Time frame
Tumor response by mRECIST;	—

Countries

China

Contacts

Public ContactWang Bo

The First Affiliated Hospital of Sun Yat-sen University

wangb45@mail.sysu.edu.cn+86 132 6597 9336

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026